Johnson & Johnson sees 2020 slide in orthopedics sales: 6 details

Laura Dyrda -   Print  |

Johnson & Johnson's orthopedics sales dropped 12.2 percent year over year in 2020 to $7.7 billion. Sales declined 10.2 percent in the U.S. and 15.2 percent worldwide.

The company attributed the drop in medical device sales to deferral of medical procedures during the pandemic, hitting its surgery, orthopedics and vision business. However, the full-year report shows market recovery during the second half of last year.

Six things to know about orthopedics sales:

1. Johnson & Johnson's medical devices segment sales dropped 11 percent in 2020, hitting nearly $23 billion.

2. Orthopedic sales dropped just 3.7 percent year over year in the fourth quarter of 2020.

3. Hip sales were down 11 percent overall, hitting $1.2 billion. In the U.S., hip sales declined 8.2 percent to $793 million.

4. Knee sales dropped 21 percent in 2020, hitting $1.1 billion. In the U.S., knee sales were down 16.4 percent to $743 million.

5. Trauma sales declined 3.9 percent to $2.6 billion overall. In the U.S., trauma sales were relatively flat year over year while trauma sales dropped 9.6 percent internationally.

6. Johnson & Johnson's spine and sports segment sales dropped 15.7 percent overall in 2020, hitting $2.6 billion. U.S. spine and sports sales were down 16.7 percent last year, hitting $1.6 billion.

More article on orthopedics:
Orthopedic implant market to hit $8.97B by 2025
1st AR knee replacement performed in US by HSS surgeon
50 things to know about 10 of the biggest orthopedic device companies

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers